Vantia's fedovapagon meets in Phase III for nocturia

Vantia Therapeutics Ltd. (Southampton, U.K.) reported top-line data from the Phase III EQUINOC trial in 432 men with benign prostatic hyperplasia (BPH) and nocturia showing that once-daily 2 mg oral fedovapagon (VA106483) met the co-primary endpoints of reducing the mean number of nocturnal voids (p<0.001) and of improving quality of life (QOL) as measured by patient-reported NocTIMe score (p=0.034) from baseline to week 12 vs. placebo.

Fedovapagon also met the secondary endpoints of improving time to first void (p<0.001), the number of nights when patients have 0 or 1 void (p<0.006) and the proportion of patients who reduced their voids by 50% (p<0.001) vs. placebo. Fedovapagon was generally well tolerated in the double-blind, U.S. trial...